Literature DB >> 31434757

Neoantigen quality, not quantity.

Nicholas McGranahan1,2, Charles Swanton1,3.   

Abstract

Prioritizing expressed clonal neoantigens in genes required for cancer cell survival may reduce the likelihood of resistance to neoantigen therapies.
Copyright © 2019 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works.

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31434757     DOI： 10.1126/scitranslmed.aax7918

Source DB:  PubMed          Journal:  Sci Transl Med        ISSN： 1946-6234            Impact factor:   17.956


  36 in total

Review 1.  Genetic and non-genetic clonal diversity in cancer evolution.

Authors:  James R M Black; Nicholas McGranahan
Journal:  Nat Rev Cancer       Date:  2021-03-16       Impact factor: 60.716

Review 2.  Neoantigen prediction and computational perspectives towards clinical benefit: recommendations from the ESMO Precision Medicine Working Group.

Authors:  L De Mattos-Arruda; M Vazquez; F Finotello; R Lepore; E Porta; J Hundal; P Amengual-Rigo; C K Y Ng; A Valencia; J Carrillo; T A Chan; V Guallar; N McGranahan; J Blanco; M Griffith
Journal:  Ann Oncol       Date:  2020-06-28       Impact factor: 32.976

3.  Negative trade-off between neoantigen repertoire breadth and the specificity of HLA-I molecules shapes antitumor immunity.

Authors:  Máté Manczinger; Balázs Koncz; Gergő Mihály Balogh; Benjamin Tamás Papp; Leó Asztalos; Lajos Kemény; Balázs Papp; Csaba Pál
Journal:  Nat Cancer       Date:  2021-07-08

4.  Comparative Molecular Life History of Spontaneous Canine and Human Gliomas.

Authors:  Samirkumar B Amin; Kevin J Anderson; C Elizabeth Boudreau; Emmanuel Martinez-Ledesma; Emre Kocakavuk; Kevin C Johnson; Floris P Barthel; Frederick S Varn; Cynthia Kassab; Xiaoyang Ling; Hoon Kim; Mary Barter; Ching C Lau; Chew Yee Ngan; Margaret Chapman; Jennifer W Koehler; James P Long; Andrew D Miller; C Ryan Miller; Brian F Porter; Daniel R Rissi; Christina Mazcko; Amy K LeBlanc; Peter J Dickinson; Rebecca A Packer; Amanda R Taylor; John H Rossmeisl; Kevin D Woolard; Amy B Heimberger; Jonathan M Levine; Roel G W Verhaak
Journal:  Cancer Cell       Date:  2020-02-10       Impact factor: 31.743

5.  Neoantigen landscape in metastatic nasopharyngeal carcinoma.

Authors:  Mei Lin; Xiao-Long Zhang; Rui You; Qi Yang; Xiong Zou; Kai Yu; You-Ping Liu; Ru-Hai Zou; Yi-Jun Hua; Pei-Yu Huang; Jin Wang; Qi Zhao; Xiao-Bing Jiang; Jun Tang; Yang-Kui Gu; Tao Yu; Gui-Ping He; Yu-Long Xie; Zhi-Qiang Wang; Ting Liu; Si-Yuan Chen; Zhi-Xiang Zuo; Ming-Yuan Chen
Journal:  Theranostics       Date:  2021-04-19       Impact factor: 11.556

Review 6.  Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC.

Authors:  Mengke Niu; Ming Yi; Ning Li; Suxia Luo; Kongming Wu
Journal:  Exp Hematol Oncol       Date:  2021-03-02

7.  Tumor mutation burden as a biomarker in resected gastric cancer via its association with immune infiltration and hypoxia.

Authors:  Deqiang Wang; Ning Wang; Xiaoqin Li; Xiaofeng Chen; Bo Shen; Dongqin Zhu; Liuqing Zhu; Yaping Xu; Yangyang Yu; Yongqian Shu
Journal:  Gastric Cancer       Date:  2021-03-09       Impact factor: 7.370

8.  CBFB-MYH11 fusion neoantigen enables T cell recognition and killing of acute myeloid leukemia.

Authors:  Melinda A Biernacki; Kimberly A Foster; Kyle B Woodward; Michael E Coon; Carrie Cummings; Tanya M Cunningham; Robson G Dossa; Michelle Brault; Jamie Stokke; Tayla M Olsen; Kelda Gardner; Elihu Estey; Soheil Meshinchi; Anthony Rongvaux; Marie Bleakley
Journal:  J Clin Invest       Date:  2020-10-01       Impact factor: 14.808

Review 9.  Acquired Resistance to Immune Checkpoint Blockades: The Underlying Mechanisms and Potential Strategies.

Authors:  Binghan Zhou; Yuan Gao; Peng Zhang; Qian Chu
Journal:  Front Immunol       Date:  2021-06-14       Impact factor: 7.561

Review 10.  TCR-like CARs and TCR-CARs targeting neoepitopes: an emerging potential.

Authors:  Mansour Poorebrahim; Niloufar Mohammadkhani; Reza Mahmoudi; Monireh Gholizadeh; Elham Fakhr; Angel Cid-Arregui
Journal:  Cancer Gene Ther       Date:  2021-03-02       Impact factor: 5.987
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.